1
|
Song J, Zeng J, Zheng S, Jiang N, Wu A, Guo S, Ye R, Hu L, Huang F, Wang L, Xiaogang Z, Liu B, Wu J, Chen Q. Sanguisorba officinalis L. promotes diabetic wound healing in rats through inflammation response mediated by macrophage. Phytother Res 2023; 37:4265-4281. [PMID: 37260161 DOI: 10.1002/ptr.7906] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 04/16/2023] [Accepted: 05/19/2023] [Indexed: 06/02/2023]
Abstract
Sanguisorba officinalis L., a traditional Chinese medicine, is frequently used to treat burns and scalds. But even so, it is unknown whether S. officinalis L. can accelerate diabetic wounds (DW) healing. Here, to bridge the gap, we employed in vivo and in vitro evaluations to assess the positive effect of S. officinalis L. ethanol extract (ESO) on DW. Results demonstrated that ESO dramatically improved the DW healing rate. With ESO treatment, the inappropriately elevated levels of IL6, IL1β and TNFα in DW were reduced, while the expression of IL10 was increased, indicating that the abnormal inflammation in DW was also under control. Moreover, the abnormally elevated expression of CD86 was significantly inhibited and the expression of CD206 was significantly up-regulated following treatment with ESO. The global level of NF-κB protein was not affected by ESO treatment, but it suppressed the expression of phosphorylated NF-κB and prevented its nuclear entry. In addition, in RAW264.7 cells activated with lipopolysaccharide (LPS), the expression of NLRP3, Caspase1 and IL1β were significantly diminished following ESO treatment. In conclusion, ESO was proved to be a promising treatment for DW healing due to its potential to accelerate the healing process by suppressing the inflammatory response. This was achieved by increasing the ratio of M2 to M1 polarization through blocking the NF-κB/NLRP3 signaling pathway.
Collapse
Affiliation(s)
- Jianying Song
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- School of Nursing, Southwest Medical University, Luzhou, China
| | - Jing Zeng
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Silin Zheng
- Department of Nursing, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Nan Jiang
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Anguo Wu
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Shengming Guo
- Department of Nursing, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Rupei Ye
- Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Lixin Hu
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- School of Nursing, Southwest Medical University, Luzhou, China
| | - Feihong Huang
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Long Wang
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Zhou Xiaogang
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Bo Liu
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- School of Nursing, Southwest Medical University, Luzhou, China
| | - Jianming Wu
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
| | - Qi Chen
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- School of Nursing, Southwest Medical University, Luzhou, China
- Department of Endocrinology and Metabolism, Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, China
- Department of Endocrinology and Metabolism, Sichuan Clinical Research Center for Nephropathy, Luzhou, China
- Department of Endocrinology and Metabolism, Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, China
| |
Collapse
|
2
|
Dammann I, Keil C, Hardewig I, Skrzydlewska E, Biernacki M, Haase H. Effects of combined cannabidiol (CBD) and hops (Humulus lupulus) terpene extract treatment on RAW 264.7 macrophage viability and inflammatory markers. NATURAL PRODUCTS AND BIOPROSPECTING 2023; 13:19. [PMID: 37284961 DOI: 10.1007/s13659-023-00382-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 05/25/2023] [Indexed: 06/08/2023]
Abstract
This study investigates the potential of cannabidiol (CBD), one major cannabinoid of the plant Cannabis sativa, alone and in combination with a terpene-enriched extract from Humulus lupulus ("Hops 1"), on the LPS-response of RAW 264.7 macrophages as an established in vitro model of inflammation. With the present study, we could support earlier findings of the anti-inflammatory potential of CBD, which showed a dose-dependent [0-5 µM] reduction in nitric oxide and tumor necrosis factor-alpha (TNF-α) released by LPS-stimulated RAW 264.7 macrophages. Moreover, we observed an additive anti-inflammatory effect after combined CBD [5 µM] and hops extract [40 µg/mL] treatment. The combination of CBD and Hops 1 showed effects in LPS-stimulated RAW 264.7 cells superior to the single substance treatments and akin to the control hydrocortisone. Furthermore, cellular CBD uptake increased dose-dependently in the presence of terpenes from Hops 1 extract. The anti-inflammatory effect of CBD and its cellular uptake positively correlated with terpene concentration, as indicated by comparison with a hemp extract containing both CBD and terpenes. These findings may contribute to the postulations for the so-called "entourage effect" between cannabinoids and terpenes and support the potential of CBD combined with phytomolecules from a non-cannabinoid source, such as hops, for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- Inga Dammann
- Sanity Group GmbH, Jägerstraße 28-31, 10117, Berlin, Germany.
| | - Claudia Keil
- Department of Food Chemistry and Toxicology, Technische Universität Berlin, Straße Des 17. Juni 135, 10623, Berlin, Germany
| | - Iris Hardewig
- Sanity Group GmbH, Jägerstraße 28-31, 10117, Berlin, Germany
| | - Elżbieta Skrzydlewska
- Department of Analytical Chemistry, Medical University of Bialystok, A. Mickiewicza 2D, 15-222, Bialystok, Poland
| | - Michał Biernacki
- Department of Analytical Chemistry, Medical University of Bialystok, A. Mickiewicza 2D, 15-222, Bialystok, Poland
| | - Hajo Haase
- Department of Food Chemistry and Toxicology, Technische Universität Berlin, Straße Des 17. Juni 135, 10623, Berlin, Germany.
| |
Collapse
|
3
|
Wang Y, Wang X, Yang Y, Quan Q, Huo T, Yang S, Ju R, An Q. Comparison of the in vitro Anti-Inflammatory Effect of Cannabidiol to Dexamethasone. CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY 2022; 15:1959-1967. [PMID: 36159203 PMCID: PMC9491233 DOI: 10.2147/ccid.s378798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 09/05/2022] [Indexed: 11/23/2022]
Abstract
Background Cannabidiol (CBD) is a non-psychoactive phytocannabinoid constituent of Cannabis sativa with pain-relieving and anti-inflammatory properties. With the emphasis on natural ingredients in cosmetics, CBD has become a new cosmetic ingredient due to its ability to alleviate inflammation. However, in-depth studies that directly compare the effective mechanism and the therapeutic potential of CBD are still needed. Purpose The aim of the present study was to investigate the anti-inflammatory effect of CBD in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and compare it to dexamethasone (DEX). Methods RAW264.7 macrophages in the logarithmic growth phase were incubated in the presence or absence of LPS. After that, the production of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. A luciferase reporter assay for nuclear factor kappa B (NF-κB) was performed, and the phosphorylation levels of the mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways were measured. Results The present study indicated that CBD had a similar anti-inflammatory effect to DEX by attenuating the LPS-induced production of NO, IL-6, and TNF-α. However, only CBD attenuated JNK phosphorylation levels, and only DEX attenuated IKK phosphorylation levels. Conclusion These results suggested that CBD and DEX exhibit similar anti-inflammatory effects on LPS-induced RAW264.7 macrophages mainly through suppressing the MAPK and NF-κB signaling pathways, but with different intracellular mechanisms. These findings suggested that CBD may be considered a natural anti-inflammatory agent for protecting skin from immune disorders.
Collapse
Affiliation(s)
- Yiming Wang
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China
| | - Xue Wang
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China
| | - Yang Yang
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China
| | - Qianghua Quan
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China
| | - Tong Huo
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China
| | - Simin Yang
- Beijing Key Laboratory of Enze Biomass Fine Chemicals, Department of Pharmaceutical Engineering, Beijing Institute of Petrochemical Technology, Beijing, People's Republic of China
| | - Ruijun Ju
- Beijing Key Laboratory of Enze Biomass Fine Chemicals, Department of Pharmaceutical Engineering, Beijing Institute of Petrochemical Technology, Beijing, People's Republic of China
| | - Quan An
- Research and Development Department, Yunnan Baiyao Group Health Products Co, Ltd, Kunming, People's Republic of China.,East Asia Skin Health Research Center, Beijing, People's Republic of China.,Research and Development Department, REAL DermaSci & Biotech Co, Ltd, Beijing, People's Republic of China.,Research and Development Department, Yunnan Baiyao Group Shanghai Science & Technology Co, Ltd, Shanghai, People's Republic of China
| |
Collapse
|
4
|
Development of Novel 1,3-Disubstituted-2-Thiohydantoin Analogues with Potent Anti-Inflammatory Activity; In Vitro and In Silico Assessments. Molecules 2022; 27:molecules27196271. [PMID: 36234810 PMCID: PMC9573447 DOI: 10.3390/molecules27196271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Revised: 09/16/2022] [Accepted: 09/20/2022] [Indexed: 11/16/2022] Open
Abstract
Inflammation is the main cause of several autoimmune diseases, including type I diabetes, rheumatoid arthritis, bullous pemphigoid, paraneoplastic pemphigoid, and multiple sclerosis. Currently, there is an urgent demand for the discovery of novel anti-inflammatory drugs with potent activity but also safe for long-term application. Toward this aim, the present study reported the design, synthesis, and characterization of a set of novel 1,3-disubstituted-2-thiohydantoins derivatives. The anti-inflammatory activity of synthesized compounds was assessed against murine leukemia cell line (RAW264.7) by evaluating the cytotoxicity activity and their potency to prevent nitric oxide (NO) production. The results revealed that the synthesized compounds possess a considerable cytotoxic activity together with the ability to reduce the NO production in murine leukemia cell line (RAW264.7). Among synthesized compounds, compound 7 exhibited the most potent cytotoxic activity with IC50 of 197.68 μg/mL, compared to celecoxib drug (IC50 value 251.2 μg/mL), and demonstrated a significant ability to diminish the NO production (six-fold reduction). Exploring the mode of action responsible for the anti-inflammatory activity revealed that compound 7 displays a significant and dose-dependent inhibitory effect on the expression of pro-inflammatory cytokines IL-1β. Furthermore, compound 7 demonstrated the ability to significantly reduce the expression of the inflammatory cytokines IL-6 and TNF-α at 50 μg/mL, as compared to Celecoxib. Finally, detailed molecular modelling studies indicated that compound 7 exhibits a substantial binding affinity toward the binding pocket of the cyclooxygenase 2 enzyme. Taken together, our study reveals that 1,3-disubstituted-2-thiohydantoin could be considered as a promising scaffold for the development of potent anti-inflammatory agents.
Collapse
|